HLTH · Cue Health Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | $17.48M | $9.90M | $24.77M | - | $69.59M | $137.42M | $64.50M | - | $223.68M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | - | $37.10M | $36.54M | $44.73M | - | $42.52M | $4.66M | $7.41M | - | $9.08M |
| SG&A | - | $15.85M | $14.70M | $16.94M | - | $25.63M | $11.38M | $11.87M | - | $3.69M |
| Total Operating Expenses | - | $82.18M | $95.29M | $120.61M | - | $137.00M | $190.16M | $49.74M | - | $136.30M |
| D&A | - | $11.20M | $10.60M | $12.06M | - | $8.30M | $10.20M | $4.88M | - | $11.40M |
| Operating Income | - | ($64.70M) | ($85.39M) | ($95.85M) | - | ($67.41M) | $64.71M | $2.85M | - | ($8.50M) |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | - | $4.73M | $0 | $0 | - | ($1.05M) | ($3.39M) | $1.23M | - | $30.10M |
| Net Income | - | ($46.97M) | ($83.86M) | ($94.20M) | - | ($66.30M) | ($99.05M) | $2.80M | - | $19.35M |
| EPS - Basic | - | ($0.31) | ($0.55) | ($0.62) | - | ($0.45) | $0.14 | $0.09 | - | ($0.52) |
| EPS - Diluted | - | ($0.31) | ($0.55) | ($0.62) | - | ($0.45) | ($0.67) | $0.02 | - | $0.13 |
Balance Sheet
| Line item | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $80.89M | $111.45M | $128.55M | $178.20M | $241.53M | $304.65M | $246.33M | $426.46M | $409.87M | $49.17M |
| Accounts Receivable | $1.35M | $1.32M | $1.71M | $9.80M | $18.75M | $24.78M | $54.01M | $75.83M | $104.59M | $4.17M |
| Inventory | $14.04M | $63.55M | $68.37M | $82.01M | $82.21M | $133.31M | $139.05M | $132.57M | $88.39M | $70.74M |
| Accounts Payable | $7.71M | $11.11M | $11.21M | $16.64M | $7.15M | $32.52M | $38.35M | $48.84M | $37.21M | $35.15M |
| Current Assets | $110.36M | $192.24M | $212.07M | $287.00M | $371.15M | $521.87M | $620.13M | $701.41M | $670.02M | $669.53M |
| Total Assets | $339.79M | $492.29M | $523.86M | $608.56M | $694.58M | $825.04M | $914.08M | $983.77M | $940.06M | $921.98M |
| Current Liabilities | $43.47M | $58.41M | $57.03M | $67.46M | $71.19M | $175.46M | $210.03M | $191.74M | $166.94M | $155.90M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $89.53M | $103.46M | $100.68M | $112.70M | $118.09M | $235.08M | $273.70M | $258.63M | $233.31M | $267.61M |
| Stockholders' Equity | $250.25M | $388.83M | $423.18M | $495.86M | $576.49M | $589.96M | $640.37M | $725.14M | $706.75M | ($84.98M) |
| Retained Earnings | ($591.54M) | ($443.11M) | ($396.14M) | ($312.27M) | ($218.07M) | ($186.57M) | ($120.27M) | ($21.21M) | ($24.02M) | ($58.25M) |
Cash Flow
| Line item | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | ($53.88M) | - | - | - | ($35.11M) | - | - |
| Investing Cash Flow | - | - | - | ($8.32M) | - | - | - | ($14.05M) | - | - |
| Financing Cash Flow | - | - | - | ($1.13M) | - | - | - | $56.64M | - | - |
| CapEx | - | - | - | $3.91M | - | - | - | $30.49M | - | - |
| Free Cash Flow | - | - | - | ($57.79M) | - | - | - | ($65.60M) | - | - |
Ratios
| Metric | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | -370.2% | -862.9% | -387.0% | - | -96.9% | 47.1% | 4.4% | - | -3.8% |
| EBITDA margin | - | -306.1% | -755.8% | -338.3% | - | -84.9% | 54.5% | 12.0% | - | 1.3% |
| Net margin | - | -268.8% | -847.5% | -380.4% | - | -95.3% | -72.1% | 4.3% | - | 8.6% |
| Free cash flow margin | - | - | - | -233.3% | - | - | - | -101.7% | - | - |
| FCF / Net income | - | - | - | 0.61 | - | - | - | -23.40 | - | - |
| R&D / Revenue | - | 212.3% | 369.2% | 180.6% | - | 61.1% | 3.4% | 11.5% | - | 4.1% |
| SG&A / Revenue | - | 90.7% | 148.6% | 68.4% | - | 36.8% | 8.3% | 18.4% | - | 1.7% |
| Effective tax rate | - | - | - | - | - | - | - | 30.4% | - | 60.9% |
| Return on assets | - | -9.5% | -16.0% | -15.5% | - | -8.0% | -10.8% | 0.3% | - | 2.1% |
| Return on equity | - | -12.1% | -19.8% | -19.0% | - | -11.2% | -15.5% | 0.4% | - | -22.8% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 2.54 | 3.29 | 3.72 | 4.25 | 5.21 | 2.97 | 2.95 | 3.66 | 4.01 | 4.29 |
| Quick ratio | 2.22 | 2.20 | 2.52 | 3.04 | 4.06 | 2.21 | 2.29 | 2.97 | 3.48 | 3.84 |
| Cash ratio | 1.86 | 1.91 | 2.25 | 2.64 | 3.39 | 1.74 | 1.17 | 2.22 | 2.46 | 0.32 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.36 | 1.27 | 1.24 | 1.23 | 1.20 | 1.40 | 1.43 | 1.36 | 1.33 | -10.85 |
| Liabilities / Assets | 0.26 | 0.21 | 0.19 | 0.19 | 0.17 | 0.28 | 0.30 | 0.26 | 0.25 | 0.29 |
| Efficiency | ||||||||||
| Asset turnover | - | 0.04 | 0.02 | 0.04 | - | 0.08 | 0.15 | 0.07 | - | 0.24 |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | 28d | 63d | 144d | - | 130d | 143d | 429d | - | 7d |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | -74.9% | -92.8% | -61.6% | - | -68.9% | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | - | 4.0% | - | - | - | -692.9% | - | - | - | - |
| Net income growth (YoY) | - | 29.2% | 15.3% | - | - | - | - | - | - | - |
| EPS growth (YoY) | - | 31.1% | 17.9% | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | 11.9% | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -56.6% | -34.1% | -33.9% | -31.6% | -18.4% | - | - | - | - | - |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2023-12-31.
Product / service
$73.44M totalProduct$64.22M · 87.5%
Grant And Other Revenue$6.71M · 9.1%
Service$2.50M · 3.4%
Peer comparison
Same SIC group: Laboratory Analytical Instruments
Comparing Cue Health Inc. against the 5 most active filers in the same SIC group.